FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311019807> ?p ?o ?g. }

• W4311019807 endingPage "31" @default.
• W4311019807 startingPage "23" @default.
• W4311019807 abstract "Abstract Objectives To prospectively assess the safety, functional‐ and oncological‐outcomes of irreversible electroporation (IRE) as salvage therapy for radio‐recurrent focal prostate cancer in a multicenter setting. Patients and methods Men with focal recurrent PCa after external beam radiation or brachytherapy without metastatic disease on staging imaging and co‐registration between mpMRI and biopsies were prospectively included in this multicenter trial. Adverse events were reported following the Clavien‐Dindo classification. Validated questionnaires were used for patient‐reported functional outcomes. Follow‐up consisted of 3 monthly prostate specific antigen (PSA) levels, a 6‐month mpMRI and standardised transperineal template mapping biopsies at 12‐months. Thereafter follow‐up was guided by MRI and/or PSMA‐PET/CT and PSA. Local recurrence was defined as any ISUP score ≥2 on biopsies. Results 37 patients were analysed with a median (interquartile range (IQR)) follow up of 29 (22–43) months. Median age was 71 (53–83), median PSA was 3.5 ng/mL (2.7–6.1). 28 (75.5%) patients harboured intermediate risk and 9 patients (24.5%) high risk PCa. Seven patients (19%) reported self‐limiting urgency, frequency, or hematuria (grade 1–2). Seven patients (19%) developed a grade 3 AE; urethral sludge requiring transurethral resection. At 12 months post treatment 93% of patients remained continent and erectile function sufficient for intercourse deteriorated from 35% to 15% (4/27). Local control was achieved in 29 patients (78%) and 27 patients (73%) were clear of local and systemic disease. Four (11%) patients had local recurrence only. Six (16%) patients developed metastatic disease with a median time to metastasis of 8 months. Conclusion The FIRE trial shows that salvage IRE after failed radiation therapy for localised PCa is safe with minimal toxicity, and promising functional and oncological outcomes. Salvage IRE can offer a possible solution for notoriously difficult to manage radio recurrent prostate tumours." @default.
• W4311019807 created "2022-12-22" @default.
• W4311019807 creator A5000385283 @default.
• W4311019807 creator A5004755566 @default.
• W4311019807 creator A5006944238 @default.
• W4311019807 creator A5010329907 @default.
• W4311019807 creator A5020534914 @default.
• W4311019807 creator A5020648785 @default.
• W4311019807 creator A5029907529 @default.
• W4311019807 creator A5036651649 @default.
• W4311019807 creator A5042043199 @default.
• W4311019807 creator A5046241521 @default.
• W4311019807 creator A5048901077 @default.
• W4311019807 creator A5054625906 @default.
• W4311019807 creator A5064761307 @default.
• W4311019807 creator A5078852863 @default.
• W4311019807 creator A5081221251 @default.
• W4311019807 creator A5086098080 @default.
• W4311019807 date "2023-01-09" @default.
• W4311019807 modified "2023-10-12" @default.
• W4311019807 title "Salvage irreversible electroporation for radio‐recurrent prostate cancer – the prospective <scp>FIRE</scp> trial" @default.
• W4311019807 cites W1494521255 @default.
• W4311019807 cites W2067125737 @default.
• W4311019807 cites W2119456602 @default.
• W4311019807 cites W2136476240 @default.
• W4311019807 cites W2137282952 @default.
• W4311019807 cites W2340422569 @default.
• W4311019807 cites W2746883747 @default.
• W4311019807 cites W2766702403 @default.
• W4311019807 cites W2883360758 @default.
• W4311019807 cites W2946040303 @default.
• W4311019807 cites W2947269630 @default.
• W4311019807 cites W2955918565 @default.
• W4311019807 cites W2985207209 @default.
• W4311019807 cites W2987877358 @default.
• W4311019807 cites W3092344805 @default.
• W4311019807 cites W3092473654 @default.
• W4311019807 cites W3136994283 @default.
• W4311019807 cites W4221072612 @default.
• W4311019807 cites W4226335820 @default.
• W4311019807 cites W4289833892 @default.
• W4311019807 doi "https://doi.org/10.1111/bju.15947" @default.
• W4311019807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36495482" @default.
• W4311019807 hasPublicationYear "2023" @default.
• W4311019807 type Work @default.
• W4311019807 citedByCount "6" @default.
• W4311019807 countsByYear W43110198072023 @default.
• W4311019807 crossrefType "journal-article" @default.
• W4311019807 hasAuthorship W4311019807A5000385283 @default.
• W4311019807 hasAuthorship W4311019807A5004755566 @default.
• W4311019807 hasAuthorship W4311019807A5006944238 @default.
• W4311019807 hasAuthorship W4311019807A5010329907 @default.
• W4311019807 hasAuthorship W4311019807A5020534914 @default.
• W4311019807 hasAuthorship W4311019807A5020648785 @default.
• W4311019807 hasAuthorship W4311019807A5029907529 @default.
• W4311019807 hasAuthorship W4311019807A5036651649 @default.
• W4311019807 hasAuthorship W4311019807A5042043199 @default.
• W4311019807 hasAuthorship W4311019807A5046241521 @default.
• W4311019807 hasAuthorship W4311019807A5048901077 @default.
• W4311019807 hasAuthorship W4311019807A5054625906 @default.
• W4311019807 hasAuthorship W4311019807A5064761307 @default.
• W4311019807 hasAuthorship W4311019807A5078852863 @default.
• W4311019807 hasAuthorship W4311019807A5081221251 @default.
• W4311019807 hasAuthorship W4311019807A5086098080 @default.
• W4311019807 hasConcept C104317684 @default.
• W4311019807 hasConcept C119060515 @default.
• W4311019807 hasConcept C121608353 @default.
• W4311019807 hasConcept C126322002 @default.
• W4311019807 hasConcept C126838900 @default.
• W4311019807 hasConcept C126894567 @default.
• W4311019807 hasConcept C141071460 @default.
• W4311019807 hasConcept C185592680 @default.
• W4311019807 hasConcept C186852380 @default.
• W4311019807 hasConcept C188816634 @default.
• W4311019807 hasConcept C197934379 @default.
• W4311019807 hasConcept C2776235491 @default.
• W4311019807 hasConcept C2776694085 @default.
• W4311019807 hasConcept C2777416452 @default.
• W4311019807 hasConcept C2778716261 @default.
• W4311019807 hasConcept C2779466945 @default.
• W4311019807 hasConcept C2780192828 @default.
• W4311019807 hasConcept C2780775027 @default.
• W4311019807 hasConcept C509974204 @default.
• W4311019807 hasConcept C55493867 @default.
• W4311019807 hasConcept C71924100 @default.
• W4311019807 hasConceptScore W4311019807C104317684 @default.
• W4311019807 hasConceptScore W4311019807C119060515 @default.
• W4311019807 hasConceptScore W4311019807C121608353 @default.
• W4311019807 hasConceptScore W4311019807C126322002 @default.
• W4311019807 hasConceptScore W4311019807C126838900 @default.
• W4311019807 hasConceptScore W4311019807C126894567 @default.
• W4311019807 hasConceptScore W4311019807C141071460 @default.
• W4311019807 hasConceptScore W4311019807C185592680 @default.
• W4311019807 hasConceptScore W4311019807C186852380 @default.
• W4311019807 hasConceptScore W4311019807C188816634 @default.
• W4311019807 hasConceptScore W4311019807C197934379 @default.
• W4311019807 hasConceptScore W4311019807C2776235491 @default.
• W4311019807 hasConceptScore W4311019807C2776694085 @default.

• next